Stay updated on KarXT Efficacy in Acutely Psychotic Schizophrenia Clinical Trial
Sign up to get notified when there's something new on the KarXT Efficacy in Acutely Psychotic Schizophrenia Clinical Trial page.

Latest updates to the KarXT Efficacy in Acutely Psychotic Schizophrenia Clinical Trial page
- Check5 days agoChange DetectedRevision: v3.5.2 was added and Revision: v3.5.0 was removed in the version history.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedSponsor line updated to Karuna Therapeutics, Inc., a Bristol Myers Squibb company.SummaryDifference0.2%

- Check34 days agoChange DetectedAdded a new revision entry v3.5.0 and removed the previous v3.4.3 entry from the Study Record Versions.SummaryDifference0.1%

- Check41 days agoChange DetectedRevision: v3.4.3 was added to the history and Revision: v3.4.2 was removed.SummaryDifference0.1%

- Check48 days agoChange DetectedThe page now presents version history with color-coded additions and deletions to help compare different versions.SummaryDifference0.1%

- Check69 days agoChange DetectedAdded Revision: v3.4.2; removed the prior funding-status notice and Revision: v3.4.1 from the history.SummaryDifference0.6%

Stay in the know with updates to KarXT Efficacy in Acutely Psychotic Schizophrenia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KarXT Efficacy in Acutely Psychotic Schizophrenia Clinical Trial page.